Technical Analysis for SESN - Sesen Bio, Inc.

Grade Last Price % Change Price Change
grade B 1.71 18.75% 0.27
SESN closed up 21.53 percent on Monday, May 20, 2019, on 3.19 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: May 21

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SESN trend table...

Date Alert Name Type % Chg
Expansion Breakout Bullish Swing Setup -2.29%
Pocket Pivot Bullish Swing Setup -2.29%
Volume Surge Other -2.29%
Wide Range Bar Range Expansion -2.29%
Stochastic Reached Overbought Strength -2.29%
Upper Bollinger Band Walk Strength -2.29%
Wide Bands Range Expansion -2.29%
Above Upper BB Strength -2.29%
Overbought Stochastic Strength -2.29%
Up 3 Days in a Row Strength -2.29%

Older signals for SESN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Cancer Solid Tumors Oncology Monoclonal Antibodies Astrazeneca Bladder Cancer Its Its Products Squamous Cell Carcinoma
Is SESN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.89
52 Week Low 0.66
Average Volume 1,897,416
200-Day Moving Average 1.3739
50-Day Moving Average 1.1024
20-Day Moving Average 1.249
10-Day Moving Average 1.307
Average True Range 0.1351
ADX 41.39
+DI 39.9778
-DI 7.5544
Chandelier Exit (Long, 3 ATRs ) 1.3447
Chandelier Exit (Short, 3 ATRs ) 1.4053
Upper Bollinger Band 1.5503
Lower Bollinger Band 0.9477
Percent B (%b) 1.33
BandWidth 48.246597
MACD Line 0.1015
MACD Signal Line 0.0671
MACD Histogram 0.0344
Fundamentals Value
Market Cap 26.93 Million
Num Shares 15.4 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 15.91
Price-to-Sales 0.56
Price-to-Book 1.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.26
Resistance 3 (R3) 2.20 1.98 2.18
Resistance 2 (R2) 1.98 1.85 2.01 2.15
Resistance 1 (R1) 1.86 1.77 1.92 1.92 2.12
Pivot Point 1.64 1.64 1.67 1.67 1.64
Support 1 (S1) 1.52 1.51 1.58 1.58 1.38
Support 2 (S2) 1.30 1.43 1.33 1.35
Support 3 (S3) 1.18 1.30 1.33
Support 4 (S4) 1.24